1-Benzoyl-DMT, also known as "DMT benzamide" or as 1-benzoyl-N,N-dimethyltryptamine, is a psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It is the 1-benzoyl derivative of DMT. The drug is a prodrug of DMT with modified pharmacokinetic properties compared to DMT in rodents. It is assumed to be cleaved into DMT by amidase enzymes. Various analogues of 1-benzoyl-DMT that are likewise DMT or 5-MeO-DMT prodrugs have also been described and have shown widely varying pharmacokinetic parameters, for instance half-life. 1-Benzoyl-DMT was first described in the literature in a patent by Terran Biosciences in 2023. It has been one of the major prodrug compounds highlighted from the patent.
See also Substituted tryptamine NBoc-DMT (N′-tert-butoxycarbonyl-DMT) 1-Acetyl-5-MeO-DMT (1A-5-MeO-DMT) N-Phosphonooxymethyl-DMT (N-POM-DMT) 1Bz-LSD (1-benzoyl-LSD)
References